NCT00444743View on ClinicalTrials.gov

Phase 2 Study of MM-093 to Treat Patients With Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2008

Conditions
Uveitis
Interventions
DRUG

MM-093

60 mg, administered subcutaneously, weekly

OTHER

Placebo

Placebo

Trial Locations (1)

02142

MERSI, Cambridge

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT00444743 - Phase 2 Study of MM-093 to Treat Patients With Uveitis | Biotech Hunter | Biotech Hunter